RESEARCH ARTICLE t c

is available at the end of the articleBackground Compliance with oral medication is often poor in pa-tients suffering from illnesses such as schizophrenia, leading to relapse and subsequent hospitalisation [1,2]. Over the past decade, a number of atypical antipsychotics have been developed as long-acting injectable depot for-mulations, with the intention of enhancing patient com-pliance and improving health outcomes [1,2]. Olanzapine long-acting injection (LAI) consists of a pamoate salt of olanzapine that is administered by deep intramuscular in-jection every 2–4 weeks. It has been available in 31coun-tries for over 5 years for the treatment of schizophrenia in adults. Clinical trials have shown that olanzapine LAI has comparable efficacy and safety to oral olanzapine with the exception of adverse events related to the route of administration [3-5]. In these trials, olanzapine LAI was associated with a cluster of symptoms related to post- * Correspondence